Immune Mechanism of Tumor Cell Lysate Combined with IL-2 Preventing Melanoma and Inhibiting Tumor Growth

Objective To investigate the preventive and inhibitory effects of tumor cell lysate(TCL) combined with IL-2 on melanoma and the potential immune mechanism. Methods The B16F10 melanoma TCL cell were prepared using an ultrasonic disruptor. Twenty-four C57BL/6 mice were randomly divided into four group...

Full description

Bibliographic Details
Main Authors: SI Yiran, YUE Jian, LIU Zhaoyang, LI Mo, ZHENG Yuanyi, WANG Xiaobing, YUAN Peng
Format: Article
Language:zho
Published: Magazine House of Cancer Research on Prevention and Treatment 2021-02-01
Series:Zhongliu Fangzhi Yanjiu
Subjects:
Online Access:http://html.rhhz.net/ZLFZYJ/html/8578.2021.20.0606.htm
_version_ 1831765861128470528
author SI Yiran
YUE Jian
LIU Zhaoyang
LI Mo
ZHENG Yuanyi
WANG Xiaobing
YUAN Peng
author_facet SI Yiran
YUE Jian
LIU Zhaoyang
LI Mo
ZHENG Yuanyi
WANG Xiaobing
YUAN Peng
author_sort SI Yiran
collection DOAJ
description Objective To investigate the preventive and inhibitory effects of tumor cell lysate(TCL) combined with IL-2 on melanoma and the potential immune mechanism. Methods The B16F10 melanoma TCL cell were prepared using an ultrasonic disruptor. Twenty-four C57BL/6 mice were randomly divided into four groups which were immunized with PBS, IL-2, TCL and TCL+IL-2 for three weeks, and contra lateral tumors were implanted in the fourth week. We observed onset time of tumor and tumor size, collected peripheral blood continuously and monitored the expression of CD4+T and CD8+T cell subsets dynamically by flow cytometry. Spleen and tumor tissues of mice were also tested for CD4+T and CD8+T cell subsets by flow cytometry and immunohistochemistry, respectively. Results The preventive immunization of the TCL+IL-2 group significantly delayed the onset time of tumor (P=0.034); moreover, the tumor volume (P=0.023) and tumor weight (P=0.0015) were also significantly smaller than those in the control group. The expression of CD8+T cell subsets in the TCL+IL-2 group and the TCL-only group were significantly higher than that in the control group (P=0.0016, P=0.012). However, the CD4+T cell subsets of the TCL+IL-2 group decreased after tumor implantation, compared with the control group (P=0.0089). The expression of CD4+T and CD8+T cell subsets in spleen and tumor tissues were as same as those in peripheral blood. Conclusion The tumor vaccine of TCL combined with IL-2 could prevent the occurrence of melanoma in mouse and effectively inhibit tumor growth by activating CD8+T cells.
first_indexed 2024-12-22T06:11:47Z
format Article
id doaj.art-c868d319a80743dd968b4eddc7f6df2f
institution Directory Open Access Journal
issn 1000-8578
1000-8578
language zho
last_indexed 2024-12-22T06:11:47Z
publishDate 2021-02-01
publisher Magazine House of Cancer Research on Prevention and Treatment
record_format Article
series Zhongliu Fangzhi Yanjiu
spelling doaj.art-c868d319a80743dd968b4eddc7f6df2f2022-12-21T18:36:14ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85781000-85782021-02-0148211512010.3971/j.issn.1000-8578.2021.20.06068578.2021.20.0606Immune Mechanism of Tumor Cell Lysate Combined with IL-2 Preventing Melanoma and Inhibiting Tumor GrowthSI Yiran0YUE Jian1LIU Zhaoyang2LI Mo3ZHENG Yuanyi4WANG Xiaobing5YUAN Peng6National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaDepartment of Ultrasound Medicine, The Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, ChinaNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaObjective To investigate the preventive and inhibitory effects of tumor cell lysate(TCL) combined with IL-2 on melanoma and the potential immune mechanism. Methods The B16F10 melanoma TCL cell were prepared using an ultrasonic disruptor. Twenty-four C57BL/6 mice were randomly divided into four groups which were immunized with PBS, IL-2, TCL and TCL+IL-2 for three weeks, and contra lateral tumors were implanted in the fourth week. We observed onset time of tumor and tumor size, collected peripheral blood continuously and monitored the expression of CD4+T and CD8+T cell subsets dynamically by flow cytometry. Spleen and tumor tissues of mice were also tested for CD4+T and CD8+T cell subsets by flow cytometry and immunohistochemistry, respectively. Results The preventive immunization of the TCL+IL-2 group significantly delayed the onset time of tumor (P=0.034); moreover, the tumor volume (P=0.023) and tumor weight (P=0.0015) were also significantly smaller than those in the control group. The expression of CD8+T cell subsets in the TCL+IL-2 group and the TCL-only group were significantly higher than that in the control group (P=0.0016, P=0.012). However, the CD4+T cell subsets of the TCL+IL-2 group decreased after tumor implantation, compared with the control group (P=0.0089). The expression of CD4+T and CD8+T cell subsets in spleen and tumor tissues were as same as those in peripheral blood. Conclusion The tumor vaccine of TCL combined with IL-2 could prevent the occurrence of melanoma in mouse and effectively inhibit tumor growth by activating CD8+T cells.http://html.rhhz.net/ZLFZYJ/html/8578.2021.20.0606.htmtumor cell lysateil-2melanomapreventiontherapy
spellingShingle SI Yiran
YUE Jian
LIU Zhaoyang
LI Mo
ZHENG Yuanyi
WANG Xiaobing
YUAN Peng
Immune Mechanism of Tumor Cell Lysate Combined with IL-2 Preventing Melanoma and Inhibiting Tumor Growth
Zhongliu Fangzhi Yanjiu
tumor cell lysate
il-2
melanoma
prevention
therapy
title Immune Mechanism of Tumor Cell Lysate Combined with IL-2 Preventing Melanoma and Inhibiting Tumor Growth
title_full Immune Mechanism of Tumor Cell Lysate Combined with IL-2 Preventing Melanoma and Inhibiting Tumor Growth
title_fullStr Immune Mechanism of Tumor Cell Lysate Combined with IL-2 Preventing Melanoma and Inhibiting Tumor Growth
title_full_unstemmed Immune Mechanism of Tumor Cell Lysate Combined with IL-2 Preventing Melanoma and Inhibiting Tumor Growth
title_short Immune Mechanism of Tumor Cell Lysate Combined with IL-2 Preventing Melanoma and Inhibiting Tumor Growth
title_sort immune mechanism of tumor cell lysate combined with il 2 preventing melanoma and inhibiting tumor growth
topic tumor cell lysate
il-2
melanoma
prevention
therapy
url http://html.rhhz.net/ZLFZYJ/html/8578.2021.20.0606.htm
work_keys_str_mv AT siyiran immunemechanismoftumorcelllysatecombinedwithil2preventingmelanomaandinhibitingtumorgrowth
AT yuejian immunemechanismoftumorcelllysatecombinedwithil2preventingmelanomaandinhibitingtumorgrowth
AT liuzhaoyang immunemechanismoftumorcelllysatecombinedwithil2preventingmelanomaandinhibitingtumorgrowth
AT limo immunemechanismoftumorcelllysatecombinedwithil2preventingmelanomaandinhibitingtumorgrowth
AT zhengyuanyi immunemechanismoftumorcelllysatecombinedwithil2preventingmelanomaandinhibitingtumorgrowth
AT wangxiaobing immunemechanismoftumorcelllysatecombinedwithil2preventingmelanomaandinhibitingtumorgrowth
AT yuanpeng immunemechanismoftumorcelllysatecombinedwithil2preventingmelanomaandinhibitingtumorgrowth